Provided by Tiger Trade Technology Pte. Ltd.

Arcus Biosciences Inc.

25.54
+0.89003.61%
Post-market: 25.18-0.3600-1.41%17:59 EDT
Volume:2.01M
Turnover:51.49M
Market Cap:3.25B
PE:-6.61
High:25.92
Open:25.31
Low:25.05
Close:24.65
52wk High:31.74
52wk Low:11.68
Shares:127.33M
Float Shares:89.84M
Volume Ratio:0.80
T/O Rate:2.24%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.8641
EPS(LYR):-3.2900
ROE:-90.82%
ROA:-30.39%
PB:7.01
PE(LYR):-7.76

Loading ...

Agenus Q2 Revenue Rises on Access and Royalty Income

Reuters
·
Aug 06

Arcus Biosciences, Inc. Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 06

Arcus Biosciences Q2 Revenue Falls Sharply on Lower License Income

Reuters
·
Aug 06

Arcus Biosciences Q2 FY26 Net Loss Widens to USD 91 Million; Revenue Drops 74.38% to USD 41 Million

Reuters
·
Aug 06

Arcus Biosciences Q2 EPS $(0.72) Beats $(0.87) Estimate, Sales $41.000M Beat $23.405M Estimate

Benzinga Earnings
·
Aug 06

Arcus Biosciences Q2 Pretax Profit USD -91 Million

Reuters
·
Aug 06

Arcus Biosciences Inc Expected to Post a Loss of 90 Cents a Share - Earnings Preview

Reuters
·
Aug 04

Arcus Biosciences (RCUS) Expands Kidney Cancer Collaboration, Is The Stock Still Undervalued?

Simply Wall St.
·
Aug 03

Bank of America Securities Sticks to Their Hold Rating for Arcus Biosciences (RCUS)

TIPRANKS
·
Aug 03

BofA Securities Adjusts Arcus Biosciences Price Target to $29 From $25

MT Newswires Live
·
Aug 03

Earning Preview: Arcus Biosciences Inc. revenue is expected to decrease by 25.80% this quarter, and institutional views are largely cautious

Earnings Agent
·
Jul 29

Arcus Biosciences Grants New Hires Stock Options for 12,600 Shares at $29.73 Each

Reuters
·
Jul 28

Arcus Biosciences Announces Clinical Supply Agreement with Aveo Oncology

Reuters
·
Jul 23

Arcus Biosciences, Summit Therapeutics Team up to Test Casdatifan-ivonescimab Combo in Kidney Cancer

Reuters
·
Jul 23

Arcus Biosciences - Aveo to Supply Tivozanib; Arcus to Sponsor Study; Each Retains Rights to Compounds

THOMSON REUTERS
·
Jul 23

Arcus Biosciences - Enrollment for New Arc-20 Cohort Expected to Begin in Q4 2026

THOMSON REUTERS
·
Jul 23

Arcus Biosciences Inc: Initial Data from This Clinical Trial Collaboration is Expected to be Generated by Mid-2027

THOMSON REUTERS
·
Jul 23

Arcus Biosciences Inc: Both Cos Will Contribute to Cost of Study, Each Co Will Retain Development & Commercial Rights to Their Respective Molecules

THOMSON REUTERS
·
Jul 23

Arcus Biosciences Inc: Under Terms of Agreement, Summit Will Supply Ivonescimab and Arcus Will Conduct and Sponsor Combination Study

THOMSON REUTERS
·
Jul 23

Arcus Biosciences and Summit Therapeutics Enter into Clinical Trial Collaboration to Evaluate Casdatifan Combined with Ivonescimab in Kidney Cancer

THOMSON REUTERS
·
Jul 23